The medication is a combination product used for managing symptomatic relief in adults experiencing balance disturbances and is relevant for symptoms linked to conditions where functional stability becomes affected. Its therapeutic focus is used for managing the disruptive symptoms related to these conditions.

Symptom Relief and Therapeutic Context

The combination is applied in the management of vertigo symptoms of various origins. The medication is relevant for easing symptoms related to dizziness and the sensation of spinning or swaying (vertigo), which are common signs of vestibular issues like Meniere's disease. It also plays a role in managing associated autonomic symptoms, specifically nausea and the urge to vomit, and is commonly used when symptoms are related to motion sickness.

This combination is applied in clinical settings that involve acute or unstable symptom patterns, particularly for recurrent or chronic dizziness. The supportive role may help patients cope more steadily with symptom fluctuations when these manifestations interfere with daily functioning.

---

Quick Fact: Relief for Vertigo Symptoms The therapy is primarily relevant for easing the acute and recurrent symptoms of vertigo (spinning dizziness) and symptoms related to heightened physiological activity, such as accompanying nausea.

Regulatory References

1. Public Assessment Report from the Dutch Medicines Evaluation Board

Арлеверт (Cinnarizine/Dimenhydrinate) is officially authorized for use only in adults 18 years and older who meet specific eligibility criteria defined in regulatory labeling. The medicine is not recommended for use in children and adolescents under 18 years, as safety and efficacy have not been established in this age group.

The medication is contraindicated and must not be used by several patient populations. These absolute restrictions include those with known hypersensitivity to the active ingredients or related antihistamines, as well as patients with severe hepatic impairment or severe renal impairment.

Furthermore, use is strictly contraindicated during pregnancy and lactation. Other non-eligible conditions include angle-closure glaucoma, epilepsy/convulsions, suspicion of raised intracranial pressure, alcohol abuse, and urine retention due to urethroprostatic disorders.

Patients with certain pre-existing conditions, such as mild to moderate renal impairment, hypertension, severe coronary heart disease, or Parkinson’s disease, are officially advised to use the medicine with caution.

The official interaction profile for the fixed-dose combination of Cinnarizine and Dimenhydrinate is primarily defined by pharmacodynamic potentiation and specific metabolic restrictions documented in regulatory labels.

Pharmacodynamic Potentiation and Restrictions

Co-administration with central nervous system (CNS) depressants, including alcohol, barbiturates, narcotic analgesics, and tranquillisers, is associated with pharmacodynamic potentiation that enhances sedative effects. Similarly, the effects of anticholinergics (e.g., tricyclic antidepressants) and Monoamine Oxidase Inhibitors (MAOIs) may be enhanced. The combination is formally restricted for use with medicines known to prolong the QT interval of the ECG (such as Class Ia and Class III anti-arrhythmics) due to the documented risk of cardiac rhythm disturbances. Additionally, the medicine may oppose the effect of Betahistine.

Metabolic and Procedural Constraints

Metabolic caution is officially advised because the Diphenhydramine component is documented to inhibit CYP2D6-mediated metabolism, which may result in an increase in the plasma concentration of co-administered sensitive substrates (e.g., neuroleptics, selective serotonin reuptake inhibitors). The medicine may also mask the response to allergy skin tests and conceal ototoxic symptoms associated with aminoglycosidic antibiotics, establishing a procedural restriction.

Population-Specific Interaction Notes

Formal contraindications are established for patients with severe hepatic impairment and severe renal impairment (creatinine clearance le 25 ml/min) due to the documented risk of reduced clearance leading to drug accumulation and increased systemic exposure.

How Арлеверт Works

Арлеверт, a fixed-dose combination drug, operates through two primary and complementary mechanistic domains to modulate key neural activity in the vestibular and emetic centers. The mechanism involves neurotransmitter receptor antagonism and ionic channel modulation to regulate overactive signaling within the vestibular system.

H1-Receptor and Central Anticholinergic Blockade

This domain involves the antagonism of central H1-histamine receptors and muscarinic acetylcholine receptors (mAChRs) in the brainstem, specifically in the vestibular nuclei and the emetic center. This combined action suppresses neurotransmission within the targeted centers, which results in the modulation of central neuronal activity.

Vestibular Sensory Signal Damping

This mechanism primarily involves the modulation of voltage-gated calcium channels on the vestibular sensory cells and associated cerebral microvessels. By regulating the influx of calcium ions, the drug modulates the excitability of the vestibular sensory pathways. This action modifies early molecular steps that shape systemic physiological outcomes, leading to an alteration of signaling patterns within targeted vestibular pathways.

The fixed-dose combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg is administered exclusively via the oral route. The established regimen focuses on precise administration timing and duration.

Official Administration Protocol

The standard adult dosing schedule is one tablet taken three times daily, representing a maximum daily intake of three tablets. For proper intake, the tablets must be swallowed whole and unchewed with some liquid. The dose is administered after meals (postprandially), a procedure designed to minimize potential gastrointestinal irritation.

Procedural Constraint	Standard Protocol
Dosing Frequency	Three times daily (divided dose).
Administration Timing	Must be taken after meals (postprandial).
Treatment Duration	Should generally not exceed four consecutive weeks

Population and Organ Function Rules

Usage is defined by age and organ function limits. The medication is not recommended for use in individuals under the age of 18 due to a lack of established data. For older adults (the elderly), no specific dose adjustment is necessary. Its use is contraindicated in patients with severe hepatic impairment or severe renal impairment (creatinine clearance leq 25 mL/min), reflecting restrictions on its metabolism and excretion.

The standardized protocol defines the fixed dose, the required postprandial timing, and a critical time limit, thereby framing the standardized clinical utilization.

Research evidence / Overview of studies for Арлеверт

Studies Evaluating Vertigo of Vestibular Origin

The primary research for this combination medicine focuses on the evaluation of outcomes related to symptoms of vertigo. The core studies included patients with conditions characterized by fluctuating or episodic manifestations of vertigo, used in research exploring how symptoms change over time. This evidence comes from multiple Randomized Controlled Trials (RCTs) that compare the fixed combination against an inactive substance (placebo) or against the individual active components used alone.

These pivotal studies were applied in studies examining patient-reported experiences, typically tracking patient-reported outcomes describing perceived discomfort. Researchers primarily measured the severity of the spinning sensation (vertigo symptom intensity) using a validated patient scale. The studies also examined outcomes related to physical discomfort, such as associated nausea and vomiting. Findings describe group patterns observed in the studies over a defined time interval.

Studies Evaluating Specific Vestibular or Vascular Conditions

This research explored short-term symptom changes in conditions linked to specific underlying causes. This included dedicated Randomized Controlled Trials (RCTs) in cohorts where symptoms associated with conditions such as Vertebrobasilar Insufficiency (VBI), or episodes of peripheral vestibular loss, were being studied. In these studies, research examined not only the change in patient-reported symptom scales but also objective outcomes reflecting daily functioning or activity level.

Data on Study Duration and Follow-up

The majority of the central controlled research for this medicine was used in trials assessing short-term or episodic symptom patterns, with the primary period of observation in these trials generally limited to 4 weeks (28 days). Research exploring short-term symptom changes helps contextualize how patients reported their experience during initial management.

However, long-term effects are not fully established. There is limited information for long-term outcomes, and the durability of any observed response over many months or years is not well characterized in the primary controlled trials. Data for extended periods are still emerging from larger, non-interventional studies, but certainty remains low regarding sustained, long-term stability.

Research in Specific Age Groups and Populations

The initial clinical trials primarily involved Adults experiencing recurrent or chronic symptoms. Researchers conducted subset analyses which included separate evaluations of the data for older adults (typically defined as those 65 years and older). Data for certain groups remain insufficient. For instance, there is limited information regarding outcomes for pregnant populations or for children, as these groups are generally excluded from the core research used for regulatory review.

What is Still Uncertain About the Research

Research contributes to the broader evidence landscape, but evidence highlights what is known—and what is still uncertain. One key research limitation frame is the duration of follow-up; the short-term focus of the main controlled trials means long-term effects are not fully established. Furthermore, certainty remains low regarding the evaluation against highly specific or rare causes of vertigo, as many studies grouped patients under a broad definition of "vestibular vertigo."

Common questions about Арлеверт (FAQ)

Q: Is Arlevert an analogue of other vestibular drugs?

Official information describes Arlevert as a fixed-dose combination medicine. Regulatory documents indicate that its two active ingredients, cinnarizine and dimenhydrinate, are reported to be more effective for reducing vertigo symptoms when used together than when either substance is used alone. This dual action is what distinguishes it from simple, single-ingredient treatments for balance disorders.

Q: Can Arlevert be taken with painkillers?

Regulatory documents advise against taking Arlevert together with narcotic analgesics (strong painkillers). This combination is associated with pharmacodynamic potentiation, which may enhance the sedative and CNS depressant effects of Arlevert.

Q: Why do some people say Arlevert didn't help?

Clinical studies have examined the medicine's outcomes for symptoms of vertigo, reporting improvement in the majority of participants. However, research findings describe group patterns and do not indicate a successful outcome for every individual. Official evidence notes that some percentage of patients in controlled trials may not report an improvement, which aligns with expected outcomes for most medical treatments.

Q: Does Arlevert affect blood pressure?

According to official product information, caution is required when using Arlevert if a person has existing low or high blood pressure, as the medicine may potentially aggravate these conditions. Furthermore, Arlevert is described as being able to enhance the effects of other medicines that are taken specifically to lower blood pressure (antihypertensives).

Q: Does Arlevert affect heart function?

Regulatory documents state that the medicine should be used with caution in individuals with severe coronary heart disease. It is also restricted for use with medicines known to prolong the heart's QT interval, such as certain anti-arrhythmics, due to the documented risk of cardiac rhythm disturbances.

Q: Are there any dietary restrictions when taking Arlevert?

Official instructions state that the tablets must be taken after meals to help minimize the potential for stomach pain or irritation. Furthermore, official documentation explicitly requires patients to avoid the consumption of alcoholic beverages while undergoing treatment, as this can enhance sedative effects.

Q: What are the vestibular disorders that Arlevert treats?

Arlevert is officially indicated for the relief of symptoms associated with various kinds of vertigo in adults. Clinical studies related to the medicine examined outcomes for conditions characterized by episodic or chronic dizziness and imbalance, including specific conditions like peripheral vestibular loss.

Q: What symptoms indicate that Arlevert might not be suitable?

Serious, though very rare, adverse reactions that are considered serious are documented in official safety profiles. These include severe allergic reactions (like rash or swelling), vision impairment, or severe blood disorders, such as aplastic anaemia. These symptoms are recognized as markers of severe unsuitability, and their occurrence is noted in regulatory materials.

Q: Can I take Arlevert if I am already taking thyroid medication?

Official product information states that caution is required if a person has an existing overactive thyroid (hyperthyroidism), as the medicine may exacerbate this condition. The topic of potential drug-drug interactions with specific thyroid medications is managed by a healthcare professional, as per standard medical practice.

Q: What to do if I missed a dose of Arlevert?

According to official regulatory guidelines, if a tablet is forgotten, the next step is to miss out on that specific dose. The next dose is described as being taken at the usual scheduled time. It is specifically stated that a double dose must not be taken to try and make up for the forgotten tablet.

Q: What happens if I stop taking Arlevert abruptly?

Official product information states that the treatment course should not be stopped sooner than instructed by a healthcare provider. If the treatment is terminated prematurely, the symptoms of vertigo (dizziness and spinning) are likely to return.

Q: Can I drive or operate complex machinery after taking Arlevert?

Official regulatory documents warn that Arlevert may cause drowsiness or fatigue (somnolence). Official documentation indicates that if a person experiences these effects, they should not operate machinery or drive vehicles due to the potential risk of impairment.

Q: Is a doctor's prescription needed to buy Arlevert?

Arlevert is officially classified as a medicinal product subject to medical prescription. Therefore, it is a prescription-only medicine in the countries where it is regulated.

Q: Can Arlevert cause addiction?

Regulatory assessment reports indicate a potential risk of abuse related to the dimenhydrinate component of the medicine. This risk is primarily linked to the possibility of the drug causing delirious effects if misused.

Q: Are cases of Arlevert overdose described in official documents?

Official patient information documents describe the symptoms that may occur in cases of overdose. These symptoms can include extreme fatigue, dizziness, shakiness, dry mouth, and rapid heartbeat. In very severe cases, more serious outcomes such as seizures, hallucinations, or coma have been reported in regulatory materials.

Q: Which official bodies approved the use of Arlevert?

Arlevert is approved and registered by the national regulatory bodies in the countries where it is marketed. This includes organizations within the European Union, as well as the regulatory bodies of the United Kingdom and Australia, among others.

Q: How does the composition of Arlevert help with ringing in the ears (tinnitus)?

While the official approved indication for the medicine is the treatment of vertigo, clinical research has also included tinnitus (ringing in the ears) as an assessed outcome. Studies indicate that some trial participants experienced a reduction in their tinnitus symptoms alongside the reduction in dizziness.

Q: Are there side effects that require urgent medical attention?

Official patient information states that in the event of rare but serious adverse effects, such as a severe allergic reaction (rash or swelling) or the appearance of symptoms described for overdose, official patient information advises that medical attention is sought immediately. These conditions represent the highest safety risk profile.

Storage and Disposal Requirements for Arlevert

Official regulatory documents define specific conditions to maintain the stability and quality of Arlevert 20 mg/40 mg tablets. The medicinal product must be stored at temperatures not exceeding 30 C.

Storage Protection

To ensure proper stability, the tablets must be kept in their original container. This requirement is mandatory for protecting the product from detrimental environmental factors, specifically light and moisture. As with all medicines, Arlevert must be stored out of the sight and reach of children.

Disposal

Regarding the disposal of unused or expired Arlevert tablets, official labeling states that there are no special requirements for its disposal. The product is not categorized as hazardous, and disposal should follow standard local procedures for non-hazardous pharmaceutical waste.